Cornelius F. Waller
Experienced in Thrombocytopenia

Cornelius F. Waller

Hugstetter Str. 55, 
Freiburg, BW, DE 
Experienced in Thrombocytopenia
Hugstetter Str. 55, 
Freiburg, BW, DE 
OverviewLocationsClinical Research

Overview

Cornelius Waller practices in Freiburg, Germany. Mr. Waller is rated as an Experienced expert by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Febrile Neutropenia, Agranulocytosis, Tissue Biopsy, and Orchiectomy.

His clinical research consists of co-authoring 93 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Hugstetter Str. 55, Freiburg, BW 79106, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis
A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drug: INCB018424/CC-4047
Study Phase: Phase 1/Phase 2
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Enrollment Status: Completed
Publish Date: February 06, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin AUC 5, Cisplatin, Pemetrexed, Nivolumab
Study Phase: Phase 2
Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients
Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drugs: Brigatinib, Tyrosine kinase inhibitor
Study Phase: Phase 2
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Drugs: Peginterferon ?2b, Nilotinib
Study Phase: Phase 3
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
Enrollment Status: Completed
Publish Date: August 20, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

93 Total Publications

First-in-Human PET Imaging of MT1-MMP in a Patient with Breast and Muscle-Invasive Urothelial Bladder Cancer Using the Bicyclic Radiotracer [68Ga]Ga-BCY25286.
First-in-Human PET Imaging of MT1-MMP in a Patient with Breast and Muscle-Invasive Urothelial Bladder Cancer Using the Bicyclic Radiotracer [68Ga]Ga-BCY25286.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Waller's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile